Dr. Todd Morgan

Yeah, I mean, we're getting better, right? The surgeries are getting better, without a doubt. It's a difficult surgery, but we're getting better at it. And we really finally understand this debate of adjuvant versus salvage radiation. And so we know what to do. And when I look at these guidelines, I mean, a lot of it is really well supported by high-level studies.

So we have a good handle on how to improve outcomes in the setting. And then, yeah, there's a ton of research to be done. All the questions that we can ask around PSMA PET and how we should change management based on PSMA PET, incredibly important. And then incorporating new therapies.

So we have a good handle on how to improve outcomes in the setting. And then, yeah, there's a ton of research to be done. All the questions that we can ask around PSMA PET and how we should change management based on PSMA PET, incredibly important. And then incorporating new therapies.

So we have a good handle on how to improve outcomes in the setting. And then, yeah, there's a ton of research to be done. All the questions that we can ask around PSMA PET and how we should change management based on PSMA PET, incredibly important. And then incorporating new therapies.

I mean, you know, androgen intensification is now a couple decades old, but we're still just understanding how to incorporate those medications into this setting. And then TBD about PARP inhibitors and other precision-based therapies. I mean, it's all out there for us to eventually do the studies and change management.

I mean, you know, androgen intensification is now a couple decades old, but we're still just understanding how to incorporate those medications into this setting. And then TBD about PARP inhibitors and other precision-based therapies. I mean, it's all out there for us to eventually do the studies and change management.

I mean, you know, androgen intensification is now a couple decades old, but we're still just understanding how to incorporate those medications into this setting. And then TBD about PARP inhibitors and other precision-based therapies. I mean, it's all out there for us to eventually do the studies and change management.

Any comments on that, Todd? No doubt. I mean, I think that's bearing out in various data sets. Thankfully, we're not treating Gleason 6 hardly anymore. Understanding better the role of surgery versus upfront radiation and virus disease is still an important question. But yeah, I mean, we're doing lots of surgeries on patients with high-risk cancers, understanding better.

Any comments on that, Todd? No doubt. I mean, I think that's bearing out in various data sets. Thankfully, we're not treating Gleason 6 hardly anymore. Understanding better the role of surgery versus upfront radiation and virus disease is still an important question. But yeah, I mean, we're doing lots of surgeries on patients with high-risk cancers, understanding better.

Any comments on that, Todd? No doubt. I mean, I think that's bearing out in various data sets. Thankfully, we're not treating Gleason 6 hardly anymore. Understanding better the role of surgery versus upfront radiation and virus disease is still an important question. But yeah, I mean, we're doing lots of surgeries on patients with high-risk cancers, understanding better.

from the get-go in transparent conversations with patients that this is, it's multimodal care. And so that's what, that's what we're planning. We're planning surgery followed eventually by radiation or homeotherapy.

from the get-go in transparent conversations with patients that this is, it's multimodal care. And so that's what, that's what we're planning. We're planning surgery followed eventually by radiation or homeotherapy.

from the get-go in transparent conversations with patients that this is, it's multimodal care. And so that's what, that's what we're planning. We're planning surgery followed eventually by radiation or homeotherapy.

Hey, thank you so much for having me. I love being on this podcast. Love, love what you're doing. Love listening to it. So great to see you.

Hey, thank you so much for having me. I love being on this podcast. Love, love what you're doing. Love listening to it. So great to see you.

Hey, thank you so much for having me. I love being on this podcast. Love, love what you're doing. Love listening to it. So great to see you.